Why is Concord Drugs falling/rising?

As of 10-Jul, Concord Drugs Ltd is experiencing a price increase, currently at Rs. 61.16, reflecting a rise of 2.91 (5.0%). The stock has recently hit a new 52-week high and has outperformed its sector by 5.57%. It has been on a consecutive gain streak for the last four days, accumulating a total return of 21.64% during this period. Additionally, the stock is trading above all key moving averages, indicating strong momentum. However, it is important to note that while the stock has generated a return of 57.14% over the past year, the company's profits have declined by 13%, and its operating profits have seen a negative CAGR growth of -4.49% over the last five years, which raises concerns about its long-term fundamental strength.
In the broader market context, Concord Drugs has significantly outperformed the benchmark Sensex, with a 1-week return of +14.77% compared to the benchmark's -0.06%. Over the past month, the stock has surged by 88.24%, while the Sensex has only increased by 0.97%. This strong performance in both the short and long term highlights the stock's market-beating capabilities. However, the decline in investor participation, with a 57.95% drop in delivery volume, suggests that while the stock is currently rising, there may be underlying concerns regarding its sustainability and investor confidence moving forward.